Skip to main content
Top
Published in: Journal of Gastroenterology 11/2019

01-11-2019 | Systemic Sclerosis | Original Article—Alimentary Tract

Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis

Authors: Shiko Kuribayashi, Sei-ichiro Motegi, Kenichiro Hara, Yasuyuki Shimoyama, Hiroko Hosaka, Akiko Sekiguchi, Kouichi Yamaguchi, Osamu Kawamura, Takeshi Hisada, Osamu Ishikawa, Motoyasu Kusano, Toshio Uraoka

Published in: Journal of Gastroenterology | Issue 11/2019

Login to get access

Abstract

Background

Esophageal motility abnormalities (EMAs) and interstitial lung diseases (ILDs) are often seen in patients with systemic sclerosis (SSc). Gastroesophageal reflux disease (GERD) could be associated with ILDs, but it is not fully understood if ILDs are caused by GERD or SSc itself.

Methods

A total of 109 patients with SSc who underwent high-resolution manometry were enrolled. Esophageal motility was diagnosed with the Chicago classification v3.0. The severity of skin thickness was evaluated by the modified Rodnan total skin thickness score (mRSS). The severity of ILDs was assessed with the chest high-resolution computer tomography (HRCT) scoring system. Relationships between EMAs, GERD, autoantibodies, skin thickness and ILDs were evaluated.

Results

44 patients had normal esophageal motility, eight had esophago-gastric junction outflow obstruction, one had distal esophageal spasm, 27 had ineffective esophageal motility and 29 had absent contractility (AC). Patients with AC had more GERD than those with normal esophageal motility (p < 0.05). The mRSS score in patients with AC was significantly higher than that in those with normal esophageal motility (p < 0.05). The HRCT score in patients with AC tended to be higher than that in those with normal esophageal motility (p = 0.05). A multivariable analysis showed that severe skin thickness was a significant predictor of AC. GERD was not a significant predictor for ILDs.

Conclusions

There were significant correlations between EMAs and severe skin thickness. GERD is not an etiology of ILDs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Matsuzaki T, Sugiyama T, Sekiguchi T, et al. Reflux esophagitis in progressive systemic sclerosis. (1) Nocturnal gastroesophageal motility in recumbent position. Nihon Shokakibyo Gakkai zasshi Jpn J Gastroenterol. 1983;80:2329–38. Matsuzaki T, Sugiyama T, Sekiguchi T, et al. Reflux esophagitis in progressive systemic sclerosis. (1) Nocturnal gastroesophageal motility in recumbent position. Nihon Shokakibyo Gakkai zasshi Jpn J Gastroenterol. 1983;80:2329–38.
2.
go back to reference Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45:346–54.CrossRef Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45:346–54.CrossRef
3.
go back to reference Matsuzaki T, Sugiyama T, Sekiguchi T, et al. A study on reflux esophagitis in progressive systemic sclerosis (PSS): second report. Nocturnal gastroesophageal motility and esophageal pH in supine position. Nihon Shokakibyo Gakkai zasshi Jpn J Gastroenterol. 1985;82:1300–7. Matsuzaki T, Sugiyama T, Sekiguchi T, et al. A study on reflux esophagitis in progressive systemic sclerosis (PSS): second report. Nocturnal gastroesophageal motility and esophageal pH in supine position. Nihon Shokakibyo Gakkai zasshi Jpn J Gastroenterol. 1985;82:1300–7.
4.
go back to reference Marie I, Ducrotte P, Denis P, et al. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1593–601.CrossRef Marie I, Ducrotte P, Denis P, et al. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1593–601.CrossRef
5.
go back to reference Roman S, Hot A, Fabien N, et al. Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. Dis Esophagus. 2011;24:299–304.CrossRef Roman S, Hot A, Fabien N, et al. Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. Dis Esophagus. 2011;24:299–304.CrossRef
6.
go back to reference Tang DM, Pathikonda M, Harrison M, et al. Symptoms and esophageal motility based on phenotypic findings of scleroderma. Dis Esophagus. 2013;26:197–203.CrossRef Tang DM, Pathikonda M, Harrison M, et al. Symptoms and esophageal motility based on phenotypic findings of scleroderma. Dis Esophagus. 2013;26:197–203.CrossRef
7.
go back to reference Crowell MD, Umar SB, Griffing WL, et al. Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life. Clin Gastroenterol Hepatol. 2017;15(207–13):e1. Crowell MD, Umar SB, Griffing WL, et al. Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life. Clin Gastroenterol Hepatol. 2017;15(207–13):e1.
8.
go back to reference Kimmel JN, Carlson DA, Hinchcliff M, et al. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil. 2016;28:1157–65.CrossRefPubMed Kimmel JN, Carlson DA, Hinchcliff M, et al. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil. 2016;28:1157–65.CrossRefPubMed
9.
go back to reference Lahcene M, Oumnia N, Matougui N, et al. Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol. 2011;2011:325826.CrossRefPubMed Lahcene M, Oumnia N, Matougui N, et al. Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol. 2011;2011:325826.CrossRefPubMed
10.
go back to reference Garrett JM, Winkelmann RK, Schlegel JF, et al. Esophageal deterioration in scleroderma. Mayo Clin Proc. 1971;46:92–6. Garrett JM, Winkelmann RK, Schlegel JF, et al. Esophageal deterioration in scleroderma. Mayo Clin Proc. 1971;46:92–6.
11.
go back to reference Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 1991;144:706–13.CrossRef Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 1991;144:706–13.CrossRef
12.
go back to reference Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med. 1978;64:998–1004.CrossRef Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med. 1978;64:998–1004.CrossRef
13.
go back to reference Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol. 1990;21:467–74.CrossRef Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol. 1990;21:467–74.CrossRef
14.
go back to reference Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179:408–13.CrossRef Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179:408–13.CrossRef
15.
go back to reference Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.CrossRefPubMed Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.CrossRefPubMed
16.
go back to reference Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–74.CrossRef Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–74.CrossRef
17.
go back to reference Kuribayashi S, Iwakiri K, Kawada A, et al. Variant parameter values-as defined by the Chicago Criteria-produced by ManoScan and a new system with Unisensor catheter. Neurogastroenterol Motil. 2015;27:188–94.CrossRef Kuribayashi S, Iwakiri K, Kawada A, et al. Variant parameter values-as defined by the Chicago Criteria-produced by ManoScan and a new system with Unisensor catheter. Neurogastroenterol Motil. 2015;27:188–94.CrossRef
18.
go back to reference LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.
19.
go back to reference Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20:1892–6. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20:1892–6.
20.
go back to reference Ooi GC, Mok MY, Tsang KW, et al. Interstitial lung disease in systemic sclerosis. Acta Radiol. 2003;44:258–64. Ooi GC, Mok MY, Tsang KW, et al. Interstitial lung disease in systemic sclerosis. Acta Radiol. 2003;44:258–64.
21.
go back to reference Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.CrossRef Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.CrossRef
22.
go back to reference Lee SW, Choi EY, Jung SY, et al. E/E’ ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in patients with systemic sclerosis. Clin Exp Rheumatol. 2010;28:S12–7. Lee SW, Choi EY, Jung SY, et al. E/E’ ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in patients with systemic sclerosis. Clin Exp Rheumatol. 2010;28:S12–7.
23.
go back to reference Carlson DA, Crowell MD, Kimmel JN, et al. Loss of peristaltic reserve, determined by multiple rapid swallows, is the most frequent esophageal motility abnormality in patients with systemic sclerosis. Clin Gastroenterol Hepatol. 2016;14:1502–6.CrossRefPubMed Carlson DA, Crowell MD, Kimmel JN, et al. Loss of peristaltic reserve, determined by multiple rapid swallows, is the most frequent esophageal motility abnormality in patients with systemic sclerosis. Clin Gastroenterol Hepatol. 2016;14:1502–6.CrossRefPubMed
24.
go back to reference Fernandez Morales A, Iniesta N, Fernandez-Codina A, et al. Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. Int J Rheum Dis. 2017;20:1582–92.CrossRef Fernandez Morales A, Iniesta N, Fernandez-Codina A, et al. Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. Int J Rheum Dis. 2017;20:1582–92.CrossRef
Metadata
Title
Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis
Authors
Shiko Kuribayashi
Sei-ichiro Motegi
Kenichiro Hara
Yasuyuki Shimoyama
Hiroko Hosaka
Akiko Sekiguchi
Kouichi Yamaguchi
Osamu Kawamura
Takeshi Hisada
Osamu Ishikawa
Motoyasu Kusano
Toshio Uraoka
Publication date
01-11-2019
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 11/2019
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01578-6

Other articles of this Issue 11/2019

Journal of Gastroenterology 11/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.